NCT07016724View on ClinicalTrials.gov

Neoadjuvant Radiochemotherapy Combined With Cadonilizumab for Local Advanced Esophageal Squamous Cell Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

208

Participants

Timeline

Start Date

August 15, 2024

Primary Completion Date

August 31, 2026

Study Completion Date

August 31, 2027

Conditions
Esophageal Squamous Cell Carcinoma
Interventions
COMBINATION_PRODUCT

cadonilizumab combined with neoadjuvant radiochemotherapy

Subjects randomized to experimental arm will be treated with PD-1/CTLA-4 bi-antibody, termed as cadonilizumab, combined with neoadjuvant radiochemotherapy before surgery.

COMBINATION_PRODUCT

neoadjuvant radiochemotherapy

Subjects in the arm 2, the control arm, will be treated with neoadjuvant radiochemotherapy.

Trial Locations (1)

450000

RECRUITING

the First Affiliated Hospital of Zhengzhou University, Zhengzhou

All Listed Sponsors
lead

The First Affiliated Hospital of Zhengzhou University

OTHER